{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:04:46Z","timestamp":1794330286091,"version":"4.9.0"},"reference-count":116,"publisher":"Informa UK Limited","issue":"9","funder":[{"name":"Medical University of Lodz, Poland"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2021,6,13]]},"DOI":"10.1080\/14656566.2021.1882997","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T05:53:07Z","timestamp":1612245187000},"page":"1203-1215","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Advances in the pharmacotherapeutic options for primary nodal peripheral T-cell lymphoma"],"prefix":"10.1080","volume":"22","author":[{"given":"Anna","family":"Wolska-Washer","sequence":"first","affiliation":[{"name":"Department of Experimental Hematology, Medical University of Lodz, Lodz. Poland"},{"name":"Copernicus Memorial Hospital, Lodz. Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Smolewski","sequence":"additional","affiliation":[{"name":"Department of Experimental Hematology, Medical University of Lodz, Lodz. Poland"},{"name":"Copernicus Memorial Hospital, Lodz. Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1744-4145","authenticated-orcid":false,"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[{"name":"Copernicus Memorial Hospital, Lodz. Poland"},{"name":"Department of Hematology, Medical University of Lodz, Lodz. Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2013.11.001"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"cit0003","doi-asserted-by":"crossref","unstructured":"Zain JM Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management. American Journal of Hematology [Internet]. 2019 [cited 2020 Aug 17];94:929\u2013946. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31119775\/.","DOI":"10.1002\/ajh.25513"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-99716-2_2"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134270"},{"issue":"10","key":"cit0006","first-page":"2188","volume":"58","author":"Tamaru J-I","year":"2017","journal-title":"Rinsho Ketsueki"},{"key":"cit0007","author":"Zhang Y","year":"2020","journal-title":"Front Oncol"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2012.05.002"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2020.05.006"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2927.2927"},{"issue":"9","key":"cit0011","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/pin.12981","volume":"70","author":"Miyoshi H","year":"2020","journal-title":"Pathol Int"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3080"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.6327"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq359"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-573089"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv201"},{"key":"cit0017","unstructured":"NCCN Clinical Practice Guidelines. T-cell Lymphoma. Version 1.2021. [cited 2020 Oct 21]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/t-cell.pdf."},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270785"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.2719"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-537514"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2020.42400"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0098"},{"key":"cit0024","unstructured":".Takeda Pharma. Adcetris (brentuximab vedotin) [package insert] Revised May 2020. [cited 2020 Oct]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/adcetris-epar-product-information_en.pdf"},{"key":"cit0025","doi-asserted-by":"crossref","unstructured":"Zhang Q, Wang S, Chen J, et al. Histone deacetylases (HDACs) guided novel therapies for T-cell lymphomas.Int J Med Sci. 2019 Jan 29;16(3):424-442.","DOI":"10.7150\/ijms.30154"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1247956"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002396"},{"key":"cit0028","unstructured":"Celgene. Istodax (romidepsin) [package insert] Revised Oct 2014. [cited 2020\u00a0Oct\u00a021]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022393s013lbl.pdf."},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-11"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13222"},{"key":"cit0032","unstructured":"EMA\/CHMP\/27767\/2013. Assessment report \u2013 Istodax. 2012;44:92. [cited 2020\u00a0Oct\u00a021]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002122\/WC500140233.pdf."},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2782"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv237"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2438_114"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1214"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"cit0038","unstructured":"Refusal of the marketing authorisation for Folotyn (pralatrexate). [cited 2020\u00a0Oct\u00a021]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/questions-answers-refusal-marketing-authorisation-folotyn-pralatrexate_en.pdf."},{"key":"cit0039","unstructured":"Pfizer. Xalkori (crizotinib) [package insert]. Revised March 2013. [cited 2020\u00a0Oct\u00a021]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/202570s016lbl.pdf."},{"key":"cit0040","first-page":"106(2):djt378","author":"Passerini CG","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"cit0041","doi-asserted-by":"crossref","unstructured":"Tsuyama N, Sakamoto K, Sakata S, et al. Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects. J Clin Exp Hematop. 2017;57(3):120-142.","DOI":"10.3960\/jslrt.17023"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.1617.1617"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134440"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0266-1"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806737"},{"key":"cit0046","first-page":"1515","volume":"130","author":"Falchi L","year":"2017","journal-title":"Blood"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001285"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-115241"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119763"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1515937"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1159\/000498905"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-132278"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2152"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13855"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2016.31.7.1160"},{"key":"cit0056","unstructured":"Merck & Co Inc. Keytruda (pembrolizumab) [package insert] Revised Jan 2020. [cited 2020\u00a0Oct\u00a021]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125514s066lbl.pdf."},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2660"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01056"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-756841"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.03.022"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000104"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000664"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.10.017"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.8793"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.6327"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00899"},{"key":"cit0067","unstructured":"Title N [Internet]. [cited 2020\u00a0Oct\u00a021]. Available from: https:\/\/www.takeda.com\/newsroom\/newsreleases\/2015\/takeda-announces-termination-of-alisertib-phase-3-trial-in-relapsed-or-refractory-peripheral-t-cell-lymphoma\/."},{"key":"cit0068","unstructured":"Merck & Co. Inc. Zolinza (vorinostat) [package insert] Revised Dec 2018. [cited 2020\u00a0Oct\u00a021]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021991s009lbl.pdf."},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12326"},{"key":"cit0070","unstructured":"Verastem Inc. Copiktra (duvelisib) [package insert]. Revised August 2018. 2020 Oct 12. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/211155Orig1Orig2s000Lbl.pdf."},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-802470"},{"key":"cit0072","unstructured":"Bayer HealthCare Pharmceuticals Inc. Aliqopa (copanlisib) [package insert]. Revised Sep 2017. [cited 2020\u00a0Oct\u00a021]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209936s000lbl.pdf."},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx289"},{"key":"cit0074","unstructured":"Yhim H-Y, Moon JH, Kim SJ, et al. Combination treatment with copanlisib, a pi3k inhibitor, and gemcitabine in relapsed or refractory peripheral t-cell lymphomas (rr-ptcl); a multicenter, open-label, phase 1\/2 trial (cosmos trial). [cited 2020\u00a0Oct\u00a021]. Available from: https:\/\/library.ehaweb.org\/eha\/2020\/eha25th\/293705\/deok-hwan.yang.combination.treatment.with.copanlisib.a.pi3.inhibitor.and.html?f=listing%3D0%2Abrowseby%3D8%Asortby%3D1%2Asearch%3Dcosmos"},{"key":"cit0075","unstructured":"Kyowa Kirin Inc. Poteligeo (mogamulizumab) [package insert]. Revised Aug 2018. [cited 2020\u00a0Oct\u00a021]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761051s000lbl.pdf."},{"key":"cit0076","first-page":"47;Suppl 1:S5-7","author":"Clinical","year":"2010","journal-title":"Semin Hematol"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3472"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.0924"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.146977"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404045"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.77"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14984"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123986"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.6.3.313"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-116277"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2438_115"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128513"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0848"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000562584.48238.c8"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0495-y"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000559412.15644.69"},{"key":"cit0092","unstructured":"Celgene. Revlimid (lenalidomide) [package insert]. Revised May 2019. [cited 2020 Oct 21]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021880s057lbl.pdf."},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-567792"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.04.029"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.573031"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29103"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1002\/hon.91_2630"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110354"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-0182-y"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14704"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01286-z"},{"key":"cit0102","unstructured":"Zinzani PL, Zhang Q, Gritti G, et al. Tislelizumab (BGB-A317) for relapsed\/refractory peripheral T cell lymphoma: safety and efficacy results from a phase 2 study. EHA Haematologica [Internet]. 2020; [cited 2020 Oct 21]. Available from: https:\/\/library.ehaweb.org\/eha\/2020\/eha25th\/293724\/pier.luigi.zinzani.tislelizumab.28bgb-a31729.for.relapsed.refractory.peripheral.html."},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000860"},{"key":"cit0104","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-115986"},{"key":"cit0105","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao3003"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.2505"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119489"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2008.04.018"},{"key":"cit0109","unstructured":"Genzyme. Lemtrada (alemtuzumab) [package insert]. Revised Oct 2017. Accessed Oct 2020. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/103948s5158lbl.pdf."},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10090339"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112076"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125017"},{"key":"cit0113","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-629543"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv624"},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.1172\/JCI94306"},{"key":"cit0116","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129559"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2021.1882997","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T23:38:56Z","timestamp":1697758736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2021.1882997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":116,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,6,13]]}},"alternative-id":["10.1080\/14656566.2021.1882997"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2021.1882997","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-11-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}